THE TAPE
$184.02▼ −0.23%
Last close
Relative strength
56RS
of 99, against every stock▲ +23 on the month
Powering up
Turning
−9.9%
six months against Pharmaceutical Preparations
52-week range
−13.5%
from the high
$153.41$212.71
Setup
blue skyplayed out
−4.7%
against the pivot at $193.02
85 days
Feb 9 · not confirmed
No US GAAP filings to read.
11/16 O 186.91 H 187.69 L 183.86 Vol 2.0M
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

RS56
vs pivot−4.66%
Tightening1.07×
Dry-up2.03×
Up/down vol-0.04
From high13%
played out6 of 9checks
Previous breakout trailed out ▼ −5.29% in Jan
Powering up
Support and resistance
Support below
$182.32
-0.9% · tested 5× · last 3 sessions ago
Resistance above
None within the last 120 sessions

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 4.2 weeks and fell 8% from its ceiling at its deepest. The pivot is $193.02, and the stock closed 4.7% below it. Its relative strength rating is 56.

Against its industry
TurningBehind its industry over six months, but ahead over one and three.
One month against its industry
+6.5%
Three months against its industry
+32.8%
Six months against its industry
-9.9%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Also on
Peers
Catalyst roadmap
85
days
Earnings in 85 days (not yet confirmed)
Feb 9, 2027
  1. Earningstentativein 85d
    Quarterly earnings
    Feb 9, 2027
How it moves on earnings

On average 3.1% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business

No figures in US GAAP filings for this company. Most foreign listings report under international standards, which this does not read.

Tracked funds

None of the tracked funds held or sold it in their latest filings.

Flagged by the market sweep
Pulled back while its group leadsTape · 2026-11-13
3 lower closes in a leading group, 50d held, at 184.38
Mixed: stocks have lagged random stocks by 1.0% over three sessions, not consistently enough to call (433 cases over 59 nights). Against their own sector they have lagged by 0.9%.
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-05
above 20d & 50d on 1.5x volume at 189.01
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
Closed above its 20- and 50-day on heavy volumeTape · 2026-10-31
above 20d & 50d on 1.9x volume at 186.65
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
GappedTape · 2026-10-31
+7.0%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-10-31
3.5 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
1
$3,249 total
Sold on the open market
0

Bought: Sharma Mani.

Not counted above: 6 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-06 Sharma Mani · See remarksaward1$186
2026-10-06 Sharma Mani · See remarksaward2$320
2026-09-08 Sharma Mani · See Remarksaward1$163
2026-08-08 Sharma Mani · See Remarksbuy20$3,249
2026-08-06 Sharma Mani · SVP, Group Controlleraward2$327
2026-07-06 Sharma Mani · See Remarksaward2$381
2026-06-08 Sharma Mani · See Remarksaward1$180

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What lines up

6 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy2
Buy7
Hold2
Sell1
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

Checking your subscription…

X-ray

The most recent of 5 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
AstraZeneca PLC (AZN) — The Tape